Latest News
Trophos Completes Efficacy Study of Olesoxime in Patients with Spinal Muscular Atrophy
Originally published on November 5, 2013. Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, […]
Read More ›Isis Reports Follow-Up Data From Phase 1 Study In Children With Spinal Muscular Atrophy
Originally published on September 19, 2013. Isis Pharmaceuticals, Inc. announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMNRx in children with spinal muscular […]
Read More ›Pfizer RG3039 Program for Spinal Muscular Atrophy Reaches Development Milestone
Originally published on September 4, 2013. Reaching the first milestone was triggered by completion of specific program activities and coincides with the successful completion of all transition obligations to Pfizer […]
Read More ›PTC Therapeutics and Roche Announce Spinal Muscular Atrophy Drug Enters First Stage of Clinical Development
Originally published on January 22, 2014. PTC announces that its SMA drug program, partnered with Roche, begins Phase I Safety Trials in healthy, adult volunteers. This brings the total number […]
Read More ›Cure Spinal Muscular Atrophy Awards $600,000 for Basic Research to Identify New Approaches for SMA Therapies
Originally published on February 20, 2014. Cure SMA is proud to announce our new basic research funding for 2014. We are leading the way to a world without SMA by […]
Read More ›Cure Spinal Muscular Atrophy Awards New Research Funding of $90,000 to Drs. Bogdanik and Lutz at The Jackson Laboratory
Originally published on February 27, 2014. Cure SMA is leading the way to a world without SMA by advancing a comprehensive research program, of which basic research is a key […]
Read More ›